Airway Administration of Budesonide Combined With Pulmonary Surfactant to Prevent Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta‐Analysis
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71308 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Kaixu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Budesonide, Pulmonary Surfactants. Die Arbeit nennt 45 Literaturangaben. Gefördert von: The authors received no specific funding for this study..
Themen: Neonatologie
Abstract (Originalsprache)
Objective
To evaluate the effectiveness and safety of using budesonide in combination with pulmonary surfactant compared with the pulmonary surfactant alone in preventing bronchopulmonary dysplasia in preterm infants.
Design
Four databases (EMBASE, MEDLINE, Web of science, and Cochrane Central) were searched for randomized controlled trials comparing the use of intratracheal budesonide in combination with pulmonary surfactant to the use of pulmonary surfactant alone. Review manager 5.3 and Stata 17 software were used for statistical analysis. Main Outcomes Measures The primary outcome was the incidence of bronchopulmonary dysplasia in the group treated with budesonide combined with pulmonary surfactant, compared to the group treated with pulmonary surfactant alone. Secondary outcomes contained mortality rate, repeated use of pulmonary surfactant, length of hospital stay, and complications.
Results
12 randomized controlled studies were included in this meta‐analysis, including 2428 preterm infants. Compared to the use of pulmonary surfactant alone, the combination of budesonide and pulmonary surfactant can significantly reduce the incidence of bronchopulmonary dysplasia ( p < 0.01, RR = 0.66, 95% CI: 0.53–0.84, low quality of evidence). Even after adjusting for the impact of publication bias, the results still indicate that the combination of budesonide and pulmonary surfactant significantly lowers the risk of BPD (RR = 0.77, 95% CI: 0.63–0.93). Additionally, it significantly decreases in‐hospital mortality rates in premature infants ( p = 0.02, RR = 0.80, 95% CI: 0.67–0.96, moderate quality of evidence), the incidence of pulmonary hemorrhage ( p < 0.01, RR = 0.61, 95% CI: 0.43–0.85, moderate quality of evidence), and the need of repeated use of pulmonary surfactant ( p < 0.01, RR = 0.52, 95% CI: 0.44–0.62, high quality of evidence). No statistically significant differences were observed in related complications.
Conclusion
Compared to the use of pulmonary surfactant alone, the combination of budesonide and pulmonary surfactant may prevent bronchopulmonary dysplasia in preterm infants, and does not increase the occurrence of related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Förderung
- The authors received no specific funding for this study.
Zitieren
APA
Wang, K., Dan, C., Gao, S., Guang, Y., & Ju, R. (2025). Airway Administration of Budesonide Combined With Pulmonary Surfactant to Prevent Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta‐Analysis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71308
Vancouver
Wang K, Dan C, Gao S, Guang Y, Ju R. Airway Administration of Budesonide Combined With Pulmonary Surfactant to Prevent Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta‐Analysis. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71308
BibTeX
@article{Wang2025,
author = {Wang, Kaixu and Dan, Chen and Gao, Shuqiang and Guang, Yue and Ju, Rong},
title = {Airway Administration of Budesonide Combined With Pulmonary Surfactant to Prevent Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta‐Analysis},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71308}
}
EUVIMED